2014 Press Releases

Keyword Search
 
2014 | 2013 | 2012 | 2011 | 2010
DateTitle 
09/29/14AVEO Oncology Announces Results from Phase 2 Clinical Studies of Tivozanib in Patients with Advanced Colorectal and Kidney Cancers Presented at ESMO 2014 Congress
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 29, 2014-- AVEO Oncology (NASDAQ:AVEO) today announced poster presentations for two Phase 2 clinical studies of tivozanib, one in metastatic colorectal cancer (mCRC) and one in renal cell carcinoma (RCC), at the 2014 Congress of the European Society for Medical Oncology (ESMO), taking place September 25–30 in Madrid, Spain. Tivozanib is an oral, potent, selective inhibitor of vascular endothelial growth factor tyro... 
Printer Friendly Version
09/29/14AVEO and Biodesix Announce Exploratory Analysis of VeriStrat-Selected Patients with Non-Small Cell Lung Cancer in Phase 2 Study of Ficlatuzumab Presented at ESMO 2014 Congress
VeriStrat “Poor” Patients Show Encouraging Overall Survival and Progression Free Survival Signal; Confirmatory Phase 2 Study Planned by Year-End MADRID--(BUSINESS WIRE)--Sep. 29, 2014-- AVEO Oncology (NASDAQ:AVEO) and Biodesix, Inc. today announced the presentation of results from a retrospective exploratory analysis using VeriStrat®, a commercially available serum protein test, to identify patients most likely to benefit from the addition of ... 
Printer Friendly Version
09/26/14AVEO Oncology Announces Presentation of AV-380 Preclinical Data at 2nd Cancer Cachexia Conference
MONTREAL--(BUSINESS WIRE)--Sep. 26, 2014-- AVEO Oncology (NASDAQ:AVEO) today announced the presentation of results from four preclinical studies of AV-380, the Company’s potent, humanized inhibitory antibody targeting growth differentiation factor 15 (GDF15), in various in vivo cachexia models and in vitro assays at the 2nd Cancer Cachexia Conference, being held September 26-28, 2014, in Montreal, Canada. In addition to the poster presentations, t... 
Printer Friendly Version
09/26/14AVEO Oncology Announces Lease Termination and Amendment to Debt Financing Facility
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 26, 2014-- AVEO Oncology (NASDAQ:AVEO) today announced that, as part of its plan to decrease operational expenses, the Company has entered into a termination of its lease agreement pertaining to the Company’s headquarters in Cambridge, Massachusetts, reducing its existing lease obligations by $110 million. In addition, the Company has amended its debt financing facility with Hercules Technology Growth Capital (HTGC... 
Printer Friendly Version
09/17/14Clinical Data on AVEO Oncology’s Ficlatuzumab and Tivozanib to Be Presented at the ESMO 2014 Congress
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 17, 2014-- AVEO Oncology (NASDAQ:AVEO) today announced that clinical data on ficlatuzumab, the Company’s hepatocyte growth factor (HGF) inhibitory antibody, as well as tivozanib, the Company’s inhibitor of vascular endothelial growth factor (VEGF) 1, 2, and 3 receptors, will be presented at the European Society of Medical Oncology (ESMO) 2014 Congress in Madrid, Spain, September 26 – September 30, 2014. ... 
Printer Friendly Version
08/11/14AVEO Oncology Reports Second Quarter 2014 Financial Results and Updates Progress on Strategic Plan
Ficlatuzumab Phase 2 NSCLC Data and Tivozanib Phase 2 CRC and RCC Data to Be Presented at ESMO 2014 Congress AV-380 Preclinical Data to Be Presented at 2nd Cancer Cachexia Conference CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 11, 2014-- AVEO Oncology (NASDAQ:AVEO) today reported its second quarter 2014 financial results and provided an update on its progress toward achieving its strategic plan. “Our strategy for building value remains fo... 
Printer Friendly Version
05/31/14AVEO Oncology Announces Presentation of AV-203 Phase 1 Results at 2014 American Society of Clinical Oncology Annual Meeting
CAMBRIDGE, Mass. & CHICAGO--(BUSINESS WIRE)--May 31, 2014-- AVEO Oncology (NASDAQ:AVEO) today announced the presentation of results from a first-in-human Phase 1 study of AV-203, AVEO’s ErbB3 (HER3) inhibitory antibody candidate. Among the results, the study established a recommended Phase 2 dose of AV-203, demonstrated good tolerability and promising early signs of activity, and reached the maximum planned dose of AV-203 monotherapy. The results wer... 
Printer Friendly Version
05/28/14AVEO Oncology to Present at the Jefferies Global Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 28, 2014-- AVEO Oncology (NASDAQ:AVEO) today announced that Tuan Ha-Ngoc, chief executive officer, is scheduled to present at the Jefferies Global Healthcare Conference on Thursday, June 5, 2014 at 8:30AM (ET) in New York City. A live webcast of AVEO’s presentation can be accessed by visiting the investors section of the company’s website at investor.aveooncology.com. A replay of the webcast will be a... 
Printer Friendly Version
05/07/14AVEO Oncology Reports First Quarter 2014 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 7, 2014-- AVEO Oncology (NASDAQ:AVEO) today reported its first quarter 2014 financial results and provided an update on its progress toward achieving its strategic plan. “We made solid progress executing on a key component of our recently announced corporate strategy, which is to advance our clinical-stage assets through collaborations while retaining substantial value,” said Tuan Ha-Ngoc, president a... 
Printer Friendly Version
05/05/14AVEO Oncology to Report First Quarter 2014 Financial Results on May 7, 2014
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 5, 2014-- AVEO Oncology (NASDAQ: AVEO) today announced that the company will release its financial results for the first quarter ended March 31, 2014 after market close on Wednesday, May 7, 2014. Management plans to host financial results conference calls on a semi-annual basis, with the Company’s next conference call in August 2014. At that time, the Company will review its mid-year financial results... 
Printer Friendly Version
04/10/14AVEO and Biodesix Partner to Co-Develop and Commercialize Ficlatuzumab with a Companion Diagnostic for Treatment of NSCLC
Biodesix to Fund Proof of Concept Study CAMBRIDGE, Mass. & BOULDER, Colo.--(BUSINESS WIRE)--Apr. 10, 2014-- AVEO Oncology (NASDAQ: AVEO) and Biodesix, Inc. today announced that they have entered into a worldwide agreement to develop and commercialize AVEO’s hepatocyte growth factor (HGF) inhibitory antibody ficlatuzumab, with a Biodesix® companion diagnostic test. This agreement and the clinical development program will leverage VeriStrat®... 
Printer Friendly Version
03/20/14AVEO Regains Worldwide Rights to AV-203
Agreement with Biogen Idec allows AVEO to seek partner to accelerate clinical development CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 20, 2014-- AVEO Oncology (NASDAQ: AVEO) today announced that it has regained worldwide rights to AV-203, a clinical-stage ErbB3 (HER3) inhibitory antibody candidate, from Biogen Idec. “We are pleased to regain rights for AV-203 as we believe in the potential of this innovative therapy and are looking forward... 
Printer Friendly Version
03/13/14AVEO Oncology Reports Full Year 2013 Financial Results and Outlines 2014 Strategic Plan
- Company ends 2013 with $118M in cash1 - - Focuses internal R&D investment on AV-380 in cachexia - - Intends to advance clinical-stage assets through strategic partnering – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 13, 2014-- AVEO Oncology (NASDAQ: AVEO) today reported consolidated 2013 financial results and outlined its 2014 strategic plan and financial guidance. “With the cost-containment measures implemented in th... 
Printer Friendly Version
03/04/14AVEO Announces Timing for Conference Call to Discuss Year-End 2013 Financial Results and Provide Strategic Update for 2014
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 4, 2014-- AVEO Oncology (NASDAQ: AVEO) today announced that financial results for the company’s fourth quarter and year ended December 31, 2013 will be released after the market closes on Thursday, March 13, 2014. AVEO will host a conference call to discuss the company’s financial results as well as provide an update on strategy for 2014 on Thursday, March 13 at 4:30 p.m. (ET). The call can be accessed by dialing 1... 
Printer Friendly Version
02/14/14AVEO and Astellas to End Worldwide Collaboration & License Agreement for Development and Commercialization of Tivozanib
Phase 2 Colorectal Cancer Study Discontinued AVEO to Outline Corporate Strategy During 2013 Financial Results Conference Call on March 13, 2014 CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)--Feb. 14, 2014-- AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced the companies will end their worldwide collaboration and license agreement for the development and commercialization of investigational agent tivozani... 
Printer Friendly Version
01/30/14AVEO and Astellas Discontinue Phase 2 Trial of Tivozanib in Breast Cancer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 30, 2014-- AVEO Oncology (NASDAQ: AVEO) today announced that AVEO and Astellas Pharma Inc. have jointly decided to discontinue the BATON (Biomarker Assessment of Tivozanib in ONcology) breast cancer clinical trial, a Phase 2 study in patients with locally recurrent or metastatic triple negative breast cancer (TNBC), due to insufficient enrollment. AVEO previously announced that enrollment in this study had b... 
Printer Friendly Version